[October 28, 2016] |
|
Viamet Pharmaceuticals Announces Presentations at ID Week 2016 on Novel Antifungal Compounds VT-1161 and VT-1129
Viamet
Pharmaceuticals, Inc., a clinical stage biopharmaceutical company,
today announced that data from preclinical studies of the novel
antifungal compounds VT-1161 and VT-1129 will be presented on Friday,
October 28th at ID Week 2016, in New Orleans, Louisiana.
VT-1161 and VT-1129 are orally-administered inhibitors of fungal CYP51.
VT-1161 is currently in Phase 2 clinical development for the treatment
of recurrent vulvovaginal candidiasis and onychomycosis. VT-1129 is
currently in Phase 1 clinical development for the treatment of
cryptococcal meningitis.
"Data generated by our collaborators at Duke University and the National
Institutes of Health highlight the exceptional potency of VT-1161 and
VT-1129 against Candida species resistant to many current antifungal
therapies, including Candida krusei and fungal pathogens isolated
from patients suffering from chronic mucocutaneous candidiasis," said
Dr. Robert Schotzinger, M.D., Ph.D., CEO of Viamet. "The increasing
resistance of fungal pathogens to current therapies poses a significant
threat and the development of new antifungal agents is a clear global
priority. Viamet is dedicated to the development of effective and safe
therapies that target a wide range of fungal pathogens and therapeutic
indications. We look forward to further discussion on the need for new
antifungal therapies at the conference and to advancing the development
of our antifungal pipeline."
Presentation details:
Friday, October 28:
|
|
|
|
Session 163 - Mycology - There's a Fungus Among Us: Treatment
|
|
|
|
|
(12:30 p.m. - 2:00 p.m. CDT (News - Alert), New Orleans Convention Center, Poster
Hall)
|
|
|
|
|
|
Presentation Number: 1635
|
|
|
|
|
|
Authors: J.V. Desai, et. al.
|
|
|
|
|
|
Presentation Title:
|
VT-1129 and VT-1161 have In Vitro Activity Against Candida
Isolates from Patients with Chronic Mucocutaneous Candidiasis
|
|
|
|
|
|
Presentation Number: 1638
|
|
|
|
|
|
Authors: W.A. Schell, et. al.
|
|
|
|
|
|
Presentation Title:
|
Investigational CYP51 Inhibitors VT-1161 and VT-1129 Show Strong
Activity In Vitro Against Candida krusei
|
|
|
|
|
|
|
About VT-1161 VT-1161 is a potent and selective,
orally-administered inhibitor of fungal CYP51 currently in Phase 2b
clinical trials for the treatment of recurrent vulvovaginal candidiasis
(RVVC) and onychomycosis. VT-1161 blocks the production of ergosterol,
an essential component of the fungal cell membrane. In preclinical and
clinical studies, VT-1161 has demonstrated broad-spectrum activity
against both Candida and dermatophyte species, including those species
that cause RVVC and onychomycosis. Given the clinical and pre-clinical
profile of VT-1161, the Company believes that it may avoid the side
effects that limit the use of current oral antifungal therapies, such as
liver toxicity and drug-drug interactions. The U.S. Food and Drug
Administration (FDA) has granted Qualified Infectious Disease Product
(QIDP) and Fast Track designations to VT-1161 for the treatment of RVVC.
There are no approved therapies in the United States for RVVC.
About VT-1129 VT-1129 is a potent and selective,
orally-administered inhibitor of fungal CYP51 currently in Phase 1
clinical trials for the treatment of cryptococcal meningitis, a
life-threatening fungal infection of the brain and the spinal cord. Oral
VT-1129 has demonstrated very high potency against Cryptococcus species,
achieves high concentrations within the central nervous system, and
markedly improves survival in preclinical models of cryptococcal
meningitis. The U.S. Food and Drug Administration (FDA) has granted
Qualified Infectious Disease Product (QIDP) and orphan designations to
VT-1129 for the treatment of cryptococcal meningitis.
About Viamet (www.viamet.com) Viamet
discovers and develops breakthrough therapies based on our leadership in
metalloenzyme chemistry and biology. Our clinical portfolio includes
novel agents to treat both chronic and life threatening fungal
infections. We also leverage our metalloenzyme expertise in other
therapeutic areas including oncology and orphan diseases. Focusing on
the needs of patients and clinicians, we design our drug candidates to
achieve superior safety and efficacy profiles compared to currently
marketed drugs.
This press release includes forward-looking statements. Actual results
may vary materially from these statements. There are many important
risks affecting Viamet's business, including that clinical trials may
not be commenced, or if commenced, may not be successful, regulatory
approvals may not be obtained and approved products, if any, may not
achieve commercial success. The Viamet group of companies includes
Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries,
Viamet Pharmaceuticals (NC), Inc., Viamet Pharmaceuticals (Bermuda),
Ltd., VPS-2, Inc. and VPS-3, Inc. The Viamet group of companies is based
in the Research Triangle Park region of North Carolina, USA.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005031/en/
[ Back To TMCnet.com's Homepage ]
|